Phase 2 trial shows 83% of adults treated with survodutide achieve significant improvement in MASH
Up to 83.0% of adults treated with survodutide (Boehringer Ingelheim and Zealand Pharma) achieved a statistically significant improvement...
top of page
Browse by category
Search
Phase III studies to investigate survodutide for people living with obesity and overweight
Boehringer Ingelheim and Zealand Pharma have initiated three Phase III trials investigating survodutide (also known as BI 456906) for...
Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesity
Boehringer Ingelheim will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for...
Browse by tag
bottom of page